RxDoctor Payments Data

Carolyn Maxwell, MD

Endocrinology, Diabetes & Metabolism · East Setauket, NYNPI 1780846808

Payments from drug & device makers

$1,314in general payments, 2019–2025

Across 18 payments — averaging $73.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$294
  • Novo Nordisk$249
  • BETA Bionics, Inc.$241
  • Medtronic$190
  • Dexcom, Inc.$140
  • Tandem Diabetes Care, Inc.$130
  • plus $70 from 3 others

What the payments were for

  • Food & beverage$1,314100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,314 in reported general payments places this provider in the 50th percentile of 804 endocrinology, diabetes & metabolism providers in New York.

See all endocrinology, diabetes & metabolism providers in New York

Medicare billing

Part B allowed, 2024
$130,972
Medicare patients
515
Services billed
1,889

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide46$94,784
MounjaroTirzepatide33$37,217
TrulicityDulaglutide16$34,580
JardianceEmpagliflozin21$20,297
Humalog Kwikpen U-100Insulin Lispro28$13,068
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$6,989
SynthroidLevothyroxine Sodium76$6,260
Levothyroxine Sodium244$5,178
Nano 2nd Gen Pen NeedlePen Needle, Diabetic32$4,716
Humulin R U-500 KwikpenInsulin Regular, Human17$4,481
Testosterone26$2,892
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic12$1,482
Metformin Hcl ErMetformin Hcl43$600
Metformin Hcl34$388
Testosterone Cypionate12$309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$249$94,78446 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 804 endocrinology, diabetes & metabolism providers in New York.

Other endocrinology, diabetes & metabolism in East Setauket

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →